News
How Palantir Is Becoming an AI Giant
In the past 25 years, software capabilities have advanced at a breakneck pace. The sheer amount of information that businesses, government agencies, and other entities have gathered encompasses the
EQS-Adhoc: Bayer Aktiengesellschaft: Monsanto announces Roundup™ class settlement agreement to resolve current and future claims
2026 Could Be a Big Year for Viking Therapeutics. Time to Buy?
Viking Therapeutics (NASDAQ: VKTX) is aiming to join one of the biggest growth industries of the times: the weight loss drug market. People hoping to lose weight have rushed to get in on GLP-1
The Best Stocks to Invest $1,000 in This February
It seems as though every industry outside of artificial intelligence (AI) is in the dumps. Even health insurance stocks had one of the wildest years in the sector's history in 2025. Why? Because of
Chemed Stock Down 15% in a Year as One Fund Builds a $5.56 Million Stake
On February 12, 2026, Barington Companies Management disclosed a new position in Chemed (NYSE:CHE), acquiring 13,000 shares in an estimated $5.56 million trade.
According to an SEC filing dated
EQS-News: Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
Prediction: Micron's Stock Price Will Be Worth This Much by the End of 2026
Smart investors already know that the artificial intelligence (AI) revolution has served as a generational bellwether for semiconductor stocks. Over the last few years, capital expenditure budgets
EVP of North America's Largest Full Truckload Company EVP Sells All Insider Shares
Michael K Liu, EVP - Operations at Knight-Swift (NYSE:KNX), disposed of 1,243 directly held shares in an open-market sale on Feb. 4, 2026, fully exiting his direct equity position according to a SEC
1 No-Brainer Dividend Stock to Buy on the Dip
Despite its fourth-quarter results being pretty solid, the share price of pharmaceutical giant AbbVie (NYSE: ABBV) fell after the company released earnings last week. The market reacted poorly to
Harvard University's Investment Manager Loads Up On 3.87M ETHA Shares
According to a SEC filing dated Feb. 13, 2026, Harvard Management Co. Inc. established a new position in the iShares Ethereum Trust ETF (NASDAQ:ETHA), acquiring 3,870,900 shares. The estimated
Better Artificial Intelligence Stock: Nvidia vs. AMD
Spending on artificial intelligence (AI) infrastructure is surging. Five companies have committed to spending $700 billion on AI infrastructure this year by themselves, while famed portfolio manager
What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years?
The pharmaceutical industry can be a tricky investment.
Remember Pfizer (NYSE: PFE) back in 2020? Its stock price shot from around $33 in February 2020 to nearly $60 by December due to its rapid
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress
On February 13, 2026, Affinity Asset Advisors disclosed a new position in Praxis Precision Medicines (NASDAQ:PRAX), acquiring 185,000 shares in an estimated $54.53 million trade.
According to a SEC
Got $500? 2 Pharma Stocks to Buy and Hold Forever.
Healthcare industry stocks are traditionally good hedges against technology and other growth stocks, because they tend to perform well when the larger stock markets do not.
But it depends on which
Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss)
By all accounts its stock should be in the red today. CRISPR Therapeutics (NASDAQ: CRSP) only reported $864,000 in fourth-quarter revenue after Thursday's closing bell, leading to a loss of $1.37
Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug?
Pharmaceutical giant Eli Lilly (NYSE: LLY) has been the winner in the massive GLP-1 drug category, the class of medications that have proven extremely effective in lowering blood sugar levels and
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026
Pfizer (NYSE: PFE) has a well-above-market dividend yield of 6.3%. Despite a payout ratio that is over 100%, the drugmaker states that it plans to maintain the dividend. But the real catalyst for a
Abbott Labs: The Healthcare Dividend Stock I'd Happily Hold Forever
You may not immediately recognize the name Abbott Laboratories (NYSE: ABT), but you've probably come into close contact with one of the company's many products -- from a coronavirus test to Ensure
1 Reason I'm Never Selling AbbVie Stock
Thirteen years ago, AbbVie (NYSE: ABBV) didn't exist -- at least not as a stand-alone company. It was an important part of Abbott Labs (NYSE: ABT) before being spun off as a separate entity. Today
Got $200? 1 Artificial Intelligence (AI) Stock to Buy and Hold for the Long Term.
Nvidia (NASDAQ: NVDA) has been the unquestioned leader in GPU chips for artificial intelligence (AI) data centers since the start of the AI boom in early 2023.
Perhaps the most impressive feat is
3 Dividend Stocks to Buy Right Now for Income and Upside
In a market where income investors have options, the 10-year Treasury yield of 4.2% serves as a "risk-free" rate. It represents the guaranteed return on government debt where principal loss is
Why Shares in This Under-the-Radar Data Center Stock Power Surged 16% Today
Shares in Advanced Energy Industries (NASDAQ: AEIS) powered higher by more than 16% as of 12:45 a.m. today. The move comes after a well-received fourth-quarter earnings report that saw the company
Is Now the Best Time to Buy Pfizer Stock?
Pfizer (NYSE: PFE) recently experienced yet another setback. The drugmaker has been posting disappointing financial results for several years, and its latest quarterly update sent its stock price
Why Solstice Advanced Materials Stock Just Popped
Solstice Advanced Materials (NASDAQ: SOLS) stock, the Honeywell (NASDAQ: HON) advanced materials and specialty chemicals division that spun off in October 2025, soared 15.2% through 12:35 a.m. ET
Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.
There are almost always some companies doing well, even when competitors in the same industry are sinking. Right now, investor enthusiasm has GLP-1 weight loss drug leader Eli Lilly (NYSE: LLY)



